Targeted Oncology

This award recognizes and celebrates exceptional achievements of individuals whose contributions have significantly influenced the field of oncology.

During a live virtual event, Ruben Mesa, MD, discussed the clinical trials and challenges of using ruxolitinib for patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Claudine Isaacs, MD, discussed treatment options for a patient with triple-negative breast cancer whose condition worsened after first-line gemcitabine plus carboplatin.

During a live virtual event, Muhamed Baljevic, MD, discussed what factors determine whether a patient with stage II multiple myeloma could receive autologous stem cell transplant.

Next steps investigating novel-based therapies for newly diagnosed metastatic renal cell carcinoma.

Advice to oncology nurses who manage patients with metastatic renal cell carcinoma receiving novel-based therapies, including lenvatinib and pembrolizumab.

An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab, based on the regimen’s performance in the CLEAR study compared with other options.

Reactions to efficacy and safety data demonstrated by the CLEAR study of lenvatinib plus pembrolizumab as first-line treatment for metastatic renal cell carcinoma.

The rationale for investigating the combinations of lenvatinib plus pembrolizumab and lenvatinib plus everolimus as frontline therapy for metastatic renal cell carcinoma.

An overview of current novel-based approaches for metastatic renal cell carcinoma and current treatment gaps.

The expert panel discusses trials underway in the adjuvant setting and the role of adjuvant therapy in patients with RCC.

Bradley McGregor, MD, reviews data from the Keynote-564 study on the use of immunotherapy in the adjuvant setting.

The expert panel discusses the role of multidisciplinary teams in treatment of patients with RCC.

Bradley McGregor, MD, reviews the case of a 62-year-old man with mRCC and the use of adjuvant therapy for RCC.

Dr Eric Jonasch and the panel discuss TIVO-3 trial data and use of tivozanib and HIF3α inhibitors in mRCC.

RCC experts discuss dose modifications and management of adverse events in patients with favorable-risk mRCC.

Eric Jonasch, MD, and the panel discuss NCCN Guidelines’ preferred second-line treatment options in mRCC.

The expert panel and Dr Eric Jonasch discuss data on first-line immunochemotherapy combinations for favorable-risk mRCC.

Eric Jonasch, MD, discusses a 62-year-old man with favorable-risk metastatic RCC and goals and treatment options for such a patient.

Renal cell carcinoma panel discusses factors impacting first-line treatment selection and patient monitoring and adverse-event management in patients with intermediate- and poor-risk mRCC.

Tom Hutson, DO, PharmD, discusses efficacy and data from CheckMate 9ER, a phase 3 study, and considerations in selecting this regimen.

The expert panel discusses practical considerations when choosing first-line treatment in mRCC in light of CLEAR trial data.

Tom Hutson, DO, PharmD, reviews data from phase 3 CLEAR trial that evaluates efficacy and safety of frontline lenvatinib and pembrolizumab or everolimus or sunitinib.

Renal cell carcinoma experts discuss key efficacy data for first-line immunotherapy combinations in intermediate- and poor-risk patients with mRCC.

The expert panel discusses systemic therapy options recommended in NCCN Guidelines for patient with intermediate- and poor-risk mRCC.

Tom Hutson, DO, PharmD, reviews the case of a 59-year-old woman with metastatic renal cell carcinoma, with intermediate risk and the role of risk assessment in patient management.

Unmet needs and future directions in the prevention and management of chemotherapy-induced neutropenia.

A discussion regarding patient selection and indications for using plinabulin, a first-in-class selective immunomodulating microtubule-binding agent, as prophylaxis against chemotherapy-induced neutropenia.

Implications for using plinabulin as prophylaxis against chemotherapy-induced neutropenia alone or in combination with other therapies based on data revealed by the Protective-1 and Protective-2 trials.